Market capitalization | $157.56m |
Enterprise Value | $139.91m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.94 |
P/S ratio (TTM) P/S ratio | 8.94 |
P/B ratio (TTM) P/B ratio | 6.41 |
Sales growth (TTM) Sales growth | 754.68% |
Turnover (TTM) Turnover | $17.63m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
6 Analysts have issued a scPharmaceuticals, Inc. forecast:
6 Analysts have issued a scPharmaceuticals, Inc. forecast:
Mar '24 |
+/-
%
|
||
Turnover | 18 18 |
756%
756%
|
|
Gross income | 12 12 |
1,133%
1,133%
|
|
EBITDA | -59 -59 |
48%
48%
|
EBIT (operating result) EBIT | -60 -60 |
48%
48%
|
Net profit | -58 -58 |
43%
43%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Head office | United States |
CEO | John Tucker |
Employees | 136 |
Founded | 2013 |
Website | www.scpharmaceuticals.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.